AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Glaukos Corporation
Video analysis: GKOS
All videosNo video analysis for this stock yet. Request one from our team.
News: GKOS
Corient Private Wealth LP Takes Position in Glaukos Corporation $GKOS
Corient Private Wealth LP acquired a new stake in Glaukos Corporation (NYSE: GKOS) during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 57,048 shares of the medical instruments supplier's stock, valued at approximately $7,973,000. Corient Private Wealth LP owned approximately 0.10% of Glaukos at the
Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue?
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?
Glaukos Corporation $GKOS Stock Holdings Trimmed by Algert Global LLC
Algert Global LLC lessened its holdings in shares of Glaukos Corporation (NYSE: GKOS) by 43.0% in the second quarter, according to its most recent filing with the SEC. The firm owned 30,871 shares of the medical instruments supplier's stock after selling 23,330 shares during the quarter. Algert Global LLC owned about 0.05% of
61,957 Shares in Glaukos Corporation $GKOS Purchased by Deutsche Bank AG
Deutsche Bank AG acquired a new stake in Glaukos Corporation (NYSE: GKOS) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 61,957 shares of the medical instruments supplier's stock, valued at approximately $8,659,000. Deutsche Bank AG owned about 0.11% of Glaukos at the
GKOS Stock Surges 67% Year to Date: What's Driving the Rally?
Glaukos' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a broader ophthalmology platform.
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.
Glaukos Announces Participation in Wells Fargo Healthcare Conference
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 3:00 p.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors.
Which Small-Cap ETF Is the Better Buy: iShares' Growth-Focused IWO or Invesco's Revenue-Weighted RWJ?
Small-cap stocks are surging, but how you own them matters more than most investors realize.
